An old group of former colleagues will be reuniting to lead a new biotech venture aimed at cultivating a portfolio to treat neuroinflammatory disorders. Led by Rick Orr, who ran the biotech Adynxx, the group is launching the startup Exalys on Thursday with $15 million in Series A funding from venture firms Catalys Pacific and […]

After reporting its TNF inhibitor reduced brain inflammation in Alzheimer’s disease patients, INmune will need to show that reducing inflammation translates into a cognitive benefit in a Phase II trial planned for next year. The study will be one of the first tests of the neuroinflammation theory as interest in the role of the immune […]

Inmune Bio Inc. CEO Raymond Tesi told BioWorld his firm is taking an “oncology-style” approach to Alzheimer’s disease (AD) as the firm tests next-generation tumor necrosis factor (TNF) inhibitor XPro-1595 against neuroinflammation. It’s working. Shares of the La Jolla-based firm (NASDAQ:INMB) closed at $15.75, up $6.90, or 78%, after the company reported interim findings from a phase Ib experiment that […]